Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 50,901

Document Document Title
WO/2019/235592A1
The present invention pertains to a pharmaceutical composition for the prevention or treatment of kidney disease, an inflammation inhibitor for the kidneys, an inflammatory cell death inhibitor for the kidneys, or a food for the preventi...  
WO/2019/235099A1
Provided is a functional food which can utilize the health-promoting effect of charcoal, can be ingested easily, has no adverse side effect, and has an effect to improve and suppress obesity. The functional food is characterized by conta...  
WO/2019/235590A1
The present invention pertains to a pharmaceutical composition for the prevention or treatment of kidney disease, a kidney inflammation inhibitor, an inflammatory cell death inhibitor for the kidneys, or a food for the prevention or impr...  
WO/2019/233810A1
The present invention is related to an inhibitor or antagonist of SHP2 for the treatment and/or prevention of a neoplastic disease.  
WO/2019/237054A1
The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to method...  
WO/2019/236636A1
The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contai...  
WO/2019/235581A1
The present inventor found that inhibition of the phosphorylation of, for example, a Ser residue in Regnase-1 is effective for treating and/or preventing a disease, etc. The present inventor also found that inhibition of the binding of, ...  
WO/2019/230558A1
Provided is an anti-inflammatory drug that is more effective and has fewer side effects in comparison to NSAIDs or steroidal anti-inflammatory drugs. Specifically, a therapeutic agent for inflammatory conditions that contains, as an acti...  
WO/2019/231824A1
Antisense oligomers and antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.  
WO/2019/230937A1
The present disclosure relates to a solid oral dosage form comprising: (i) (S)-4-amino-5-chloro-N-[{4-[(1-hydroxyacetyl-4-piperidinyl)m ethyl]-2-morpholinyl}methyl]-2-methoxybenzamide, a pharmaceutically acceptable salt thereof, or a hyd...  
WO/2019/228788A1
The present invention relates to new herbicidally active 2-bromo-6-alkoxyphenyl-substituted pyrrolin-2-ones according to general formula (I) or agrochemically acceptable salts thereof, and the use of these compounds for controlling weeds...  
WO/2019/225741A1
The present invention provides a nephrotic syndrome therapeutic or prophylactic agent which contains N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole-3-yl)-1H-i ndole-6-yl]-N-methyl-(2S)-2-(morpholine-4-yl) propanamide, or a pharmaceuti...  
WO/2019/226529A1
This disclosure is related to methods of making and using a multi-protein complex. The complex can create a multivalent binding mechanism for multiple targets in a solution or on a surface. The complex has various applications, and can b...  
WO/2019/225924A1
The present invention relates to: sustained-release microparticles capable of maintaining, for a long time, effects of preventing, treating or alleviating benign prostatic hyperplasia and prostate cancer and effects of preventing hair lo...  
WO/2019/226750A1
The invention provides methods of treating and preventing renal inflammation by reducing the concentration or altering the structure of a one or more UDP hexoses, such as UDP-glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-gluc...  
WO/2019/226548A1
Methods are provided to prevent and to treat urogenital (e.g., urovaginal) atrophy syndrome of menopause by using a vasodilator such as an angiotensin receptor blocker, ACE inhibitor, or calcium channel blocker. More particularly, the me...  
WO/2019/225768A1
Provided is a therapeutic or prophylactic agent for pain or interstitial cystitis comprising N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-lH-indazol-3-yl)-lH-in dol-6-yl]-N- methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically accept...  
WO/2019/218995A1
Provided is a method for the biomimetic culture of urothelial cells from mammalian bladders, including murine, porcine, bovine and human sources to isolate and expand urothelial cells for use in various applications, such as intravesical...  
WO/2019/219584A1
The present invention relates to new herbicidally active spiro cyclohexyl pyrrolin-2-ones according to general formula (I) or agrochemically acceptable salts thereof, and the use of these compounds for controlling weeds and weed grasses ...  
WO/2019/222559A1
Methods for testing the effects of therapeutic compound candidates on a phenotypic organoid model is provided. Such a method includes steps of generating the phenotypic organoid model on a high throughput screening platform, treating the...  
WO/2019/219587A1
The present invention relates to novel herbicidally active 2-bromo-6-alkoxyphenyl-substituted pyrrolin-2-ones according to general formula (I) or agrochemically acceptable salts thereof, and to their use for controlling unwanted grasses ...  
WO/2019/221269A1
Provided are: a complex having an anti-human MUC1 antibody Fab fragment, a peptide linker and/or a ligand; a diagnostic composition and/or a medicinal composition comprising said complex; and a method for diagnosing and/or treating cance...  
WO/2018/227063A8
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.  
WO/2019/217091A1
Provided herein are methods of using mesenchymal stromal/stem cell (MCS) exosomes in the treatment of diseases associated with thymic dysfunction. In some embodiments, the MSC exosomes restore thymic architecture and development in a sub...  
WO/2019/216360A1
The present invention addresses the problem of providing a prophylactic or therapeutic agent which is for prostate cancer and which can be produced simply and inexpensively, and contains, as an active ingredient, a low molecular weight c...  
WO/2019/216294A1
The purpose of the present invention is to provide compounds having an M3 PAM action. Examples of the present invention include azabenzimidazole compounds represented, for example, by formula [I], and pharmacologically acceptable salts t...  
WO/2019/215470A1
The present invention relates to the use of Guanabenz or derivates thereof for the treatment of type I IFN-dependent pathologies.The inventors investigate here how pharmacological interference with the eIF2α-P pathway can be beneficial ...  
WO/2019/215090A1
The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition...  
WO/2019/215268A1
The present invention relates to cyclopentane compounds of Formula (I), physical forms thereof, processes for their production and their use in medicine.  
WO/2019/217373A1
The present invention includes compositions and methods for treating or preventing renal or kidney stones in a human subject. In certain embodiments, the subject is administered certain ENPP1 polypeptides or ENPP3 polypeptides, mutants, ...  
WO/2019/212935A1
The invention provides methods of monitoring development of renal inflammation in a subject who has an infection by analyzing levels of one or more UDP-hexoses, such as UDP- glucose, UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-gluco...  
WO/2019/211394A1
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...  
WO/2019/210638A1
A dexamethasone-loaded macrophage-derived microvesicle, a preparation method therefor, and an application thereof. The dexamethasone-loaded macrophage-derived microvesicle is formed by loading dexamethasone in a microvesicle derived from...  
WO/2019/213006A1
Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other condition...  
WO/2019/212966A1
A wet pet food product is provided, comprising a complete food for a companion animal, the food including less than 1.0 g/Mcal inorganic phosphate. One or more citrate salts may also be included, desirably in an amount less than 0.5 wt.%...  
WO/2019/213558A1
The present disclosure is related to methods and compositions for treating or preventing kidney injury or failure, comprising administering an endothelin B (ETB) receptor agonist and/or an α2 adrenergic agent.  
WO/2019/213005A1
The present invention relates to compounds, compositions and methods for treating diseases or conditions mediated by proteins of the SWI/SNF chromatin-remodeling complex, including PB1.  
WO/2019/207014A1
A compound of formula (I), (I) wherein R10 is H or C1-6 alkyl such as Me; R2 is H, -(CH2)pCOOH, -(CH2)pCON(R5)2 or -(CH2)pCOOC1-6alkyl; each R5 is H or C1-6 alkyl; each R1 is independently selected from H, halo (e.g. fluoro or chloro), C...  
WO/2019/208725A1
A pharmaceutical composition comprising abiraterone acetate ester particles having an average particle diameter of 50 to 200 nm and hydroxypropyl cellulose in an amount of 10 to 150% by mass relative to the content of abiraterone acetate...  
WO/2019/208797A1
Provided is a novel compound that has an excellent β-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent β-lactamase inhibitory effect or a pharmaceutical...  
WO/2019/208777A1
One of the problems to be solved by the present invention is to provide an inhibitor of renal disorder induced by an iodine contrast medium. In the present invention, use is made of cilastatin or a pharmaceutically acceptable salt thereof.  
WO/2019/208820A1
The present invention relates to: a complex that includes (1) nanoparticles, (2) an enzyme inhibitor–containing group represented by formula (A), (3) a ligand-containing group represented by general formula (L1) and supported by the su...  
WO/2019/208635A1
Provided are: a compound having a xanthine oxidase inhibitory activity, represented by general formula (I) (in the formula: R1 is a group or an atom selected from a hydrogen atom, a C1-C8 alkyl group, a C1-C8 alkyl group substituted with...  
WO/2019/208805A1
The present invention addresses the problem of finding an effective preventive and/or therapeutic agent for an autoimmune disease, in particular, pemphigus, pemphigoid or ANCA-related angiitis and thus providing the same as a medicine. A...  
WO/2019/208812A1
A compound represented by general formula (1), a salt thereof, or a prodrug thereof is provided as a compound effective in the prevention and/or treatment of fibrosis. (In the formula, A is an optionally substituted benzene ring; B is an...  
WO/2019/204537A1
The invention provides compounds having the general formula (I): or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R7a, R7b, X, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compos...  
WO/2019/201311A1
The present invention provides isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, isolated polynucleotide segment encoding the isolate...  
WO/2019/201707A1
The present invention relates to a substance mixture which comprises a mixture of potassium citrate and magnesium citrate for use as a medicament for various indications. In particular, the invention relates to a substance mixture for ad...  
WO/2019/201755A1
The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.  
WO/2019/202767A1
The purpose of the present invention is to provide a molecule having a significant effect on the development of fibrosis and a substance capable of inhibiting fibrosis. This biomarker for fibrosis comprises RNA binding motif protein 7 (R...  

Matches 501 - 550 out of 50,901